The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison

Annals of Oncology : Official Journal of the European Society for Medical Oncology
I HerthPeter Dreger

Abstract

In a single-center retrospective donor versus no-donor comparison, we investigated if allogeneic stem cell transplantation (alloSCT) can improve the dismal course of poor-risk chronic lymphocytic leukemia (CLL). All patients with CLL who were referred for evaluation of alloSCT within a 7-year time frame and had a donor search indication according to the EBMT criteria or because of Richter's transformation were included. Patients for whom a matched donor could be found within 3 months (matches) were compared with patients without such a donor (controls). Primary end point was overall survival measured from the 3-month landmark after search initiation. Of 105 patients with donor search, 97 (matches 83; controls 14) were assessable at the 3-month landmark. Matches and controls were comparable for age, gender, time from diagnosis, number of previous regimens, and remission status. Disregarding if alloSCT was actually carried out or not, survival from the 3-month landmark was significantly better in matches versus controls [hazard ratio 0.38, 95% confidence interval (CI) 0.17-0.85; P = 0.014]. The survival benefit of matches remained significant on multivariate analysis. This study provides first comparative evidence that alloSCT ma...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ScheteligUNKNOWN Cooperative German Transplant Study Group
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaUNKNOWN Hx-CD20-406 Study Investigators
Mar 8, 2012·Blood·Thorsten ZenzStephan Stilgenbauer
Nov 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GhielminiUNKNOWN Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma
Dec 28, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier C BadouxAlessandra Ferrajoli
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien

❮ Previous
Next ❯

Citations

Nov 29, 2012·Current Hematologic Malignancy Reports·L SellnerT Zenz
Dec 3, 2014·Hematology/oncology Clinics of North America·Fabienne McClanahan, John Gribben
Feb 17, 2015·Future Oncology·Philip A ThompsonMichael J Keating
Sep 2, 2014·Leukemia Research·Cynthia L Toze, Alina S Gerrie
Feb 6, 2015·Current Hematologic Malignancy Reports·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC)
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Oct 16, 2016·Best Practice & Research. Clinical Haematology·Mohamed A Kharfan-DabajaErnesto Ayala
Oct 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed A Kharfan-DabajaBipin N Savani
Apr 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emili Montserrat, Peter Dreger
Apr 9, 2017·Annals of Hematology·C ShustikS Coutre
Oct 18, 2014·Therapeutic Advances in Hematology·Prerna Mewawalla, Sunita Nathan
May 13, 2018·Blood·John G Gribben

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Carol MorenoEmili Montserrat
Hematology/oncology Clinics of North America
Peter Dreger, European Group for Blood and Marrow Transplantation (EBMT)
© 2021 Meta ULC. All rights reserved